Table 1.

Ongoing (not yet recruiting; recruiting; enrolling by invitation; active, not recruiting) clinical trials with low-molecular-weight compounds combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (May 2021).

Compound	Trade Name	Manufacturer	Molecular Target	Number of Clinical Trials	Reference
Etoposide	Vepesid®	Bristol-Myers Squibb, New York, NY, USA	Topoisomerase II	40	[33]
Lenalidomide	Revlimid®	Celgene corporation, Summit, CO, USA	Cereblon, Ikaros transcription factors	18	[34]
Ibrutinib	Imbruvica®	Pharmacyclics, Synnyvale, CA, USA	Bruton’s tyrosine kinase	4	[35]
Chidamide	Epidaza®	Schenzen Chipscreen, Shenzhen, China	Histone deacetylases	4	[36]
Nelarabine	Arranon®	GlaxoSmithKline, London, Great Britain	DNA synthesis	4	[37]
Azacitidine	Vidaza®	Bristol-Myers Squibb, New York, NY, USA		3	[38]
Decitabine	Dacogen®	Janssen Pharmaceuticals, Beerse, Belgium		3	[39]
Venetoclax	Venclexta®	Genentech, South San Francisco, CA, USA	B-cell lymphoma-2 protein	3	[40]
Dasatinib	Sprycel®	Bristol-Myers Squibb, New York, NY, USA	BCR-ABL 1 tyrosine kinase	3	[41]
Ponatinib	Iclusig®	ARIAD Pharmaceuticals, Cambridge, MA, USA		2	[42]
Romidepsin	Istodax®	Gloucester Pharmaceuticals, Cambridge, MA, USA	Histone deacetylases	2	[43]
Vorinostat	Zolinza®	Merck & Co., Kenilworth, IL, USA		2	[44]
Bortezomib	Velcade®	Takeda Pharmaceutical Company Limited, Tokyo, Japan	26S proteasome	2	[45]
Ixazomib	Ninlaro®		Proteasome subunit beta type-5	2	[46]
Acalabrutinib	Calquence®	AstraZeneca, Cambridge, Great Britain	Bruton’s tyrosine kinase	2	[47]
Zanubrutinib	Brukinsa®	BeiGene, Beijing, China		2	[48]
Umbralisib	Ukoniq®	Rhizen Pharmaceuticals AG, Basel, Switzerland	Phosphatidylinositol 3-kinase delta	2	[49]
Parsaclisib	n.a. 2	Innovent Biologics, Suzhou, China		1	[50]
Pralatrexate	Folotyn®	Allos Therapeutics, Westminster, CO, USA	Dihydrofolate reductase	1	[51]
Duvelisib	Copiktra®	Verastem Oncology, Needham, MA, USA	Phosphatidylinositol 3-kinase	1	[52]
Copansilib	Aliqopa®	Bayer, Leverkusen, Germany		1	[53]
Selinexor	n.a.	Karyopharm Therapeutics, Newton, MA, USA	Exportin-1	1	[54]
Iberdomide	n.a.	Celgene Corporation, Summit, CO, USA	Cereblon	1	[55]
TAK-659	n.a.	Takeda Pharmaceutical Company Limited, Tokyo, Japan	Spleen tyrosine kinase	1	[56]
Carfilzomib	Kyprolis®	Amgen, Thousand Oaks, CA, USA	20S proteasome	1	[57]

¹ breakpoint cluster region-Abelson proto-oncogene; ² a trading name not available.